Charles Boulakia's practice is principally directed towards the preparation and prosecution of patent applications in the biotechnology and pharmaceutical areas.

Charles Boulakia is a partner of Ridout & Maybee LLP in the firm's Toronto office. His practice is principally directed towards the preparation and prosecution of patent applications in the biotechnology and pharmaceutical areas. Charles provides his clients with IP due diligence, validity, and freedom to operate opinions. He advises on food and drug regulatory law, including product labelling and advertising.

B.Sc. (Biochemistry), 1993, McGill University
M.Sc. (Biochemistry), 1996, McGill University
Combined M.B.A./LL.B., 2000, University of Western Ontario
Barrister & Solicitor, Province of Ontario, 2002
Registered Trade-mark Agent, Canada, 2004
Registered Patent Agent, Canada, 2005

Intellectual Property Institute of Canada (IPIC), Affiliate
Canadian Bar Association (CBA)
The Biotechnology Iniative, Communications Committee
Chemical Institute of Canada (CIC)
Licensing Executives Society (LES), Toronto Chapter, Co-Chair
Member of Editorial Board of CLB's Canadian Patent Reporter (CPR)

Boulakia, CA and Doug Wilson “Proposed Amendments to Drug Patent Regulations Assist Both Innovative and Generic Drug Manufacturers” Legal Alert, (March 2005)

Boulakia, CA and C Tape. "New Canadian Regulations for Natural Health Products" FDLI Update, March/April 2004

Jazairi, J and CA Boulakia. "New Canadian Labelling Requirements for Most Pre-Packaged Foods" Regulatory Affairs Focus July 2003

Dawar, N and CA Boulakia. "Brands as Mental Real Estate" Ivey Business Journal September 1999

Boulakia CA et al., "Bcl-2 and adenovirus E1B 19kDa protein prevent E1A induced processing of CPP32 and cleavage of poly (ADP-ribose) polymerase" (1996) Oncogene 12, 529-535